Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| FSD Pharma Inc | HUGE | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.438 | 03:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.438 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.4184 - 1.6799 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.438 | USD |
FSD Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 16.94M | 38.50M | - | 0 | -23.61M | -0.61 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
FSD Pharma News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HUGE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.47 | 0.52 | 0.42 | 0.4651271 | 334,931 | -0.032 | -6.81% |
| 1 Month | 0.673 | 0.72 | 0.4184 | 0.5060245 | 195,185 | -0.235 | -34.92% |
| 3 Months | 0.815 | 1.09 | 0.4184 | 0.6972504 | 184,202 | -0.377 | -46.26% |
| 6 Months | 0.97 | 1.50 | 0.4184 | 0.8575844 | 142,321 | -0.532 | -54.85% |
| 1 Year | 1.44 | 1.6799 | 0.4184 | 1.08 | 139,924 | -1.00 | -69.58% |
| 3 Years | 1.78 | 2.25 | 0.4184 | 1.34 | 176,466 | -1.34 | -75.39% |
| 5 Years | 8.0497 | 14.00 | 0.4184 | 2.37 | 480,673 | -7.61 | -94.56% |
FSD Pharma Description
| FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative and inflammatory disorders. The three licensed drug candidates are LUCID-MS, a new chemical entity targeting multiple sclerosis, LUCID-PSYCH, a psychoactive molecule targeting major depressive disorder, and FSD-PEA, an ultra-micronized palmitoyl ethylamine with a favorable safety profile targeting inflammation. |
